Jacobs Levy Equity Management, Inc Amylyx Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 478,440 shares of AMLX stock, worth $1.91 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
478,440
Previous 589,111
18.79%
Holding current value
$1.91 Million
Previous $1.12 Million
38.52%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$18.6 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$10.7 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$8.5 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$8.09 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $234M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...